Royal Bank Of Canada Eye Point Pharmaceuticals, Inc. Transaction History
Royal Bank Of Canada
- $479 Billion
- Q4 2024
A detailed history of Royal Bank Of Canada transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 6,083 shares of EYPT stock, worth $38,140. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,083
Previous 6,284
3.2%
Holding current value
$38,140
Previous $50,000
10.0%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding EYPT
# of Institutions
156Shares Held
72.4MCall Options Held
187KPut Options Held
225K-
Cormorant Asset Management, LP Boston, MA8.33MShares$52.2 Million4.9% of portfolio
-
Suvretta Capital Management, LLC New York, NY6.78MShares$42.5 Million2.1% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA5.75MShares$36.1 Million0.08% of portfolio
-
Franklin Resources Inc San Mateo, CA4.14MShares$25.9 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.8MShares$23.8 Million0.0% of portfolio
About EyePoint Pharmaceuticals, Inc.
- Ticker EYPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,072,200
- Market Cap $214M
- Description
- EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...